RMC No. 123-2021 updates the VAT-exempt COVID-19 medicines and vaccine list, affecting pharmacies, hospitals, importers, and healthcare suppliers.
Pharmacies, hospitals, healthcare suppliers, importers, distributors, wholesalers, and retailers dealing in COVID-19 medicines must immediately check their product master lists, invoices, point-of-sale systems, and importation records against the updated VAT-exempt list published under RMC No. 123-2021. The most important change is that the VAT exemption for COVID-19 treatment products under Republic Act No. 11534, or the CREATE Act, now covers additional medicines and an additional COVID-19 vaccine entry, provided the product, strength, dosage form, and regulatory authorization match the updated list.
What RMC No. 123-2021 Changed
RMC No. 123-2021 publishes the Department of Health endorsement of updates to the List of VAT-Exempt Drugs and Vaccines Prescribed and Directly Used for COVID-19 Treatment under Section 109(1)(AA) of the Tax Code, as amended by Republic Act No. 11534. For businesses, the practical effect is simple but important: products appearing in the updated list should be treated as VAT-exempt, while products not covered by the list should not automatically be treated as exempt.
The update matters because VAT exemption for COVID-19 medicines is product-specific. It is not enough that a drug is generally used in healthcare, or that it is broadly related to COVID-19 treatment. Businesses must verify the generic name, strength, form, and applicable authorization or reference in the updated list before removing 12% VAT from the sale or importation.
The new entries identified in the endorsement include investigational COVID-19 drugs such as Baricitinib in 2 mg and 4 mg film-coated tablet forms, and Amoxicillin 500 mg film-coated tablet. The endorsement also includes a COVID-19 vaccine under Emergency Use Authorization, referring to a SARS-CoV-2 recombinant spike protein nanoparticle vaccine entry in 0.5 mL suspension for injection form. The updated list attached to the issuance also contains multiple drugs and vaccines prescribed and directly used for COVID-19 treatment, grouped by regulatory category, including products under compassionate special permit, emergency use authorization, and Philippine COVID-19 living recommendations.
Who Is Most Affected
The affected taxpayers are businesses in the medical, pharmaceutical, hospital, distribution, and importation chain. This includes drugstores, pharmacies, hospital pharmacies, private hospitals, clinics, healthcare procurement offices, pharmaceutical importers, manufacturers, distributors, wholesalers, retailers, and corporate taxpayers that purchase COVID-19 treatment medicines in bulk for healthcare operations.
The issuance is especially important for VAT-registered sellers and importers because a product that becomes VAT-exempt must be invoiced and accounted for differently from a VATable product. CFOs, accountants, and tax managers should review whether their accounting system properly distinguishes VAT-exempt COVID-19 medicines from VATable medicines, medical supplies, and other healthcare products.
For procurement teams, the key commercial issue is pricing. A VAT-exempt product should not carry output VAT in the invoice. If the product is mistakenly treated as VATable, the buyer may be charged an avoidable 12% VAT component. If the product is mistakenly treated as exempt when it is not within the updated list, the seller may face BIR questions on under-declared output VAT.
Key Compliance Requirements and Dates
RMC No. 123-2021 was issued on December 14, 2021. The Department of Health endorsement letter is dated November 17, 2021. Businesses should use the updated list published through the circular as the reference for VAT treatment of covered COVID-19 medicines and vaccines.
The compliance requirement is not merely to identify the generic name of the medicine. The updated list is organized by generic name, strength, form, and reference or authorization. This means that the tax treatment should be checked at the stock keeping unit level. For example, where the list identifies a specific strength and form, the invoice, import entry, purchase order, and product registration documents should be consistent with that listed description.
A critical clarification in the issuance concerns salt forms. If the salt form of a medicine in the COVID-19 VAT-exempt list is not specified, all salt forms of that particular drug are covered by the VAT exemption. The endorsement gives Meropenem as an example: for Meropenem 1 g powder or 500 mg powder, the VAT exemption covers all salt forms, including sodium or trihydrate. This is a useful clarification for pharmacies and importers because product labels and regulatory documents may use different salt descriptions for the same active drug.
Businesses should also note the scope of the list: it refers to drugs and vaccines prescribed and directly used for COVID-19 treatment. It should not be read as a blanket VAT exemption for all medicines, all antibiotics, all vaccines, or all medical products. The safer approach is to match each item to the listed generic name, strength, and form before applying VAT-exempt treatment.
Penalties and Audit Risk for Non-Compliance
RMC No. 123-2021 does not create a special penalty table or new surcharge specific to the updated COVID-19 medicines list. However, the absence of a special penalty does not make the update optional. If a seller incorrectly treats a VATable product as VAT-exempt, the issue may be raised in a BIR examination as a VAT compliance matter. If a seller continues to charge VAT on a product that is covered by the VAT-exempt list, the buyer may question the pricing and the seller may need to correct its invoicing and tax reporting treatment.
The main risk is classification error. Because the exemption depends on a detailed list, businesses should avoid relying only on brand names, general therapeutic categories, or informal descriptions. The better control is to maintain an internal mapping of product code, generic name, strength, dosage form, supplier documentation, and VAT status.
Practical Steps for Pharmacies, Importers, Hospitals, and Accountants
First, tax and accounting teams should update their VAT master file for COVID-19 medicines and vaccines. Each covered product should be tagged as VAT-exempt only after confirming the generic name, strength, and form in the updated list.
Second, procurement and inventory teams should coordinate with suppliers to obtain product documents that match the list. This is particularly important for imported products and products with Emergency Use Authorization or compassionate special permit documentation.
Third, point-of-sale and billing systems should be reviewed. For retail pharmacies and hospital pharmacies, a wrong tax code in the POS system can cause recurring VAT errors across thousands of transactions.
Fourth, finance teams should review open purchase orders, invoices, and import entries for covered products around the December 14, 2021 issuance date. The goal is to determine whether corrections or system updates are needed for products newly covered by the updated list.
Fifth, businesses should document the basis for VAT-exempt treatment. A simple file containing the product description, supplier document, regulatory authorization where applicable, and internal VAT classification approval can help defend the treatment in case of BIR review.
Common Search Questions Answered
For taxpayers searching for RMC 123-2021 VAT-exempt COVID-19 medicines, the key answer is that the circular updates the list of COVID-19 treatment drugs and vaccines that may be sold or imported VAT-free under the CREATE Act. For those searching for Baricitinib VAT exemption Philippines, the updated list includes Baricitinib 2 mg and 4 mg film-coated tablets. For those searching for VAT exemption salt form medicines, the circular clarifies that where no salt form is specified, all salt forms of the listed drug are covered. For those searching for COVID-19 vaccine VAT exemption BIR, the update includes an additional vaccine entry under Emergency Use Authorization.
How Ablola, Saribong & Gueco Can Help
Ablola, Saribong & Gueco assists pharmacies, hospitals, importers, healthcare suppliers, and corporate taxpayers in reviewing VAT classification, BIR compliance exposure, invoicing practices, and documentation for VAT-exempt medicines and medical products. Our tax and business law team can help determine whether specific products qualify for VAT exemption, prepare internal compliance guidance, and assist in responding to BIR inquiries or audit findings involving VAT treatment.
For legal and tax assistance on RMC No. 123-2021, VAT-exempt COVID-19 medicines, healthcare importation, or BIR compliance reviews, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.